glp 1 for prader willi New commentary offers practical guidance on GLP-1 use in Prader-Willi syndrome Glucagon-like peptide-1 receptor: mechanisms and
Description
By focusing on GLP-1 medications such as semaglutide and tirzepatide, Nalena addresses weight gain challenges that often slip under the radar of generic diet and fitness plans
It also discusses the challenges, such as cost, access and long-term safety, and also examines the potential for precision medicine strategies to enhance their impact on the global CVD burden [15,16]
Most patients experience significant weight regain after stopping GLP-1 medications, with clinical trials showing regain of substantial weight within the first year
While this approach may work short term, it often triggers the bodys natural defense mechanisms
Notably, the study did not mention an increased fracture risk associated with semaglutide, despite the fact that this information is currently reported elsewhere [80]
